Loading company…
Ouro Medicines develops therapies for chronic immune-mediated diseases.
Ouro Medicines develops therapies intended to reset the immune system, including OM336, a T cell engager designed to deplete proinflammatory cells. The company also has discovery programs targeting subsets of B cells. Founded in 2025, it is based in South San Francisco, US. In March 2026, Gilead Sciences agreed to acquire it for USD 1.68 billion upfront and USD 500 million in potential milestone payments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in